Get the Stockscreener App
9.31
6.43%
-0.64
After Hours:
9.31
Dyne Therapeutics Inc stock is traded at $9.31, with a volume of 2.22M.
It is down -6.43% in the last 24 hours and down -2.72% over the past month.
Dyne Therapeutics Inc is a clinical-stage neuromuscular disease company focused on discovering and advancing life-transforming therapeutics for people living with genetically driven neuromuscular diseases. Its FORCE platform develops targeted therapeutics that are designed to overcome limitations in delivery to muscle tissue and the central nervous system, or CNS. Its FORCE platform therapeutics consist of a payload that is rationally designed to target the genetic basis of the disease are seeking to treat, a linker, and an antigen-binding fragment, that attaches to the payload using the linker. Its Pipeline includes DYNE-101, DYNE-251, DYNE-302, and DYNE-401.
See More
Previous Close:
$9.95
Open:
$9.97
24h Volume:
2.22M
Relative Volume:
0.79
Market Cap:
$1.06B
Revenue:
-
Net Income/Loss:
$-294.51M
P/E Ratio:
-2.6152
EPS:
-3.56
Net Cash Flow:
$-244.42M
1W Performance:
+1.53%
1M Performance:
-2.72%
6M Performance:
-30.83%
1Y Performance:
-79.09%
1-Day Range:
$9.25
$9.97
1-Week Range:
$9.00
$10.23
52-Week Range:
$6.36
$47.45
Dyne Therapeutics Inc Stock (DYN) Company Profile
Name
Dyne Therapeutics Inc
Sector
Industry
Phone
(781) 786-8230
Address
1560 TRAPELO ROAD, WALTHAM
Compare DYN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DYN
Dyne Therapeutics Inc
|
9.31 | 1.41B | 0 | -294.51M | -244.42M | -3.56 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.83 | 120.60B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
558.63 | 60.80B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
324.79 | 42.87B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
595.19 | 36.23B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
294.51 | 31.54B | 3.81B | -644.79M | -669.77M | -6.24 |
Dyne Therapeutics Inc Stock (DYN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-25 | Initiated | Bernstein | Mkt Perform |
| Jun-11-25 | Resumed | Raymond James | Outperform |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| May-29-25 | Initiated | Evercore ISI | Outperform |
| Mar-12-25 | Initiated | BMO Capital Markets | Outperform |
| Mar-07-25 | Initiated | Scotiabank | Sector Outperform |
| Dec-13-24 | Initiated | Robert W. Baird | Outperform |
| Nov-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | JP Morgan | Overweight → Neutral |
| May-21-24 | Reiterated | Chardan Capital Markets | Buy |
| Apr-30-24 | Initiated | Morgan Stanley | Overweight |
| Feb-20-24 | Initiated | H.C. Wainwright | Buy |
| Feb-27-23 | Upgrade | Raymond James | Outperform → Strong Buy |
| Feb-15-23 | Initiated | Oppenheimer | Outperform |
| Jan-26-23 | Initiated | Guggenheim | Buy |
| Jul-20-22 | Initiated | Chardan Capital Markets | Buy |
| Jul-12-22 | Initiated | Raymond James | Outperform |
| Oct-12-20 | Initiated | JP Morgan | Overweight |
| Oct-12-20 | Initiated | Jefferies | Buy |
| Oct-12-20 | Initiated | Piper Sandler | Overweight |
| Oct-12-20 | Initiated | Stifel | Buy |
View All
Dyne Therapeutics Inc Stock (DYN) Latest News
Dyne Therapeutics Narrowed Its Loss And Won Analyst Support - Finimize
Dyne Therapeutics extends cash runway as it advances key drug programs - Investing.com Australia
Dyne Therapeutics, Inc. Q2 Loss Increases, Misses Estimates - Nasdaq
Dyne (DYN) Expects Funding to Sustain Operations Through 2027 - GuruFocus
Dyne (DYN) Advances Clinical Programs and Strengthens Financial Position - GuruFocus
Dyne Therapeutics Extends Cash Runway to Q3 2027, Advances Clinical Trials for DM1 and DMD - Quiver Quantitative
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights | DYN Stock News - GuruFocus
Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire
What is the risk reward ratio of investing in Dyne Therapeutics Inc. stockDiscover breakthrough investment opportunities - jammulinksnews.com
Why is Dyne Therapeutics Inc. stock attracting strong analyst attentionUnlock exclusive trading strategies for gains - jammulinksnews.com
How many analysts rate Dyne Therapeutics Inc. as a “Buy”Exceptional market positioning - jammulinksnews.com
What is Dyne Therapeutics Inc. company’s growth strategyDiscover market opportunities with expert help - jammulinksnews.com
Should I hold or sell Dyne Therapeutics Inc. stock in 2025Breakthrough investment results - jammulinksnews.com
What makes Dyne Therapeutics Inc. stock price move sharplyRecord-setting profit potential - jammulinksnews.com
What are analysts’ price targets for Dyne Therapeutics Inc. in the next 12 monthsGet insider insights into market trends - jammulinksnews.com
What is the dividend policy of Dyne Therapeutics Inc. stockFind the best stocks for sustainable growth - jammulinksnews.com
What are the technical indicators suggesting about Dyne Therapeutics Inc.Track emerging stocks with high growth potential - jammulinksnews.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dyne Therapeutics, Inc.DYN - ETX View
Dyne Therapeutics Inc. Stock Analysis and ForecastBreakout profit opportunities - Autocar Professional
What analysts say about Dyne Therapeutics Inc. stockFree Stock Market Return Analysis - Autocar Professional
What drives Dyne Therapeutics Inc. stock priceSuperior risk-adjusted returns - jammulinksnews.com
Is Dyne Therapeutics Inc. a good long term investmentGame-changing returns - Autocar Professional
Dyne Therapeutics (NASDAQ:DYN) Price Target Lowered to $9.00 at JPMorgan Chase & Co. - MarketBeat
Hedge Fund and Insider Trading News: Bill Ackman, Warren Buffett, Ray Dalio, Scott Bessent, Elliott Management, Citadel Investment Group, Balyasny Asset Management, Qualys Inc (QLYS), Dyne Therapeutics Inc (DYN), and More - Insider Monkey
Dyne Therapeutics (DYN) Stock Rises as CEO Increases Stake - GuruFocus
Dyne shares up after CEO buys stock (DYN:NASDAQ) - Seeking Alpha
Former Biogen VP Who Led SPINRAZA Success Joins Satellos to Advance DMD Treatment - Stock Titan
Dyne Therapeutics price target lowered to $41 from $46 at Evercore ISI - MSN
Strategic Confidence in Dyne Therapeutics: Insider Backing and Breakthroughs in Rare Disease Therapies - AInvest
DYN CEO Makes Significant Stock Purchase, Shares Rise | DYN Stoc - GuruFocus
How to Take Advantage of moves in (DYN) - news.stocktradersdaily.com
Dyne Therapeutics Inc Stock (DYN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.32%
1.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):